FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients

Ilaria Mancini, Carla Valsecchi, Luca Andrea Lotta, Louis Deforche, Silvia Pontiggia, Mariateresa Bajetta, Roberta Palla, Karen Vanhoorelbeke, Flora Peyvandi

Research output: Contribution to journalArticle

Abstract

Collagen-binding activity (CBA) and FRETS-VWF73 assays are widely adopted methods for the measurement of the plasmatic activity of ADAMTS13, the von Willebrand factor (VWF) cleaving-protease. Accurately assessing the severe deficiency of ADAMTS13 is important in the management of thrombotic thrombocytopenic purpura (TTP). However, non-concordant results between the two assays have been reported in a small but relevant percentage of TTP cases. We investigated whether CBA or FRETS-VWF73 assay reflects ADAMTS13 proteolytic activity in acquired TTP patients with non-concordant measurements. Twenty plasma samples with non-concordant ADAMTS13 activity results,

Original languageEnglish
Pages (from-to)297-303
Number of pages7
JournalThrombosis and Haemostasis
Volume112
Issue number2
DOIs
Publication statusPublished - 2014

Keywords

  • ADAMTS13 activity assay
  • Autoantibodies
  • Flow assay
  • TTP
  • Von Willebrand factor

ASJC Scopus subject areas

  • Hematology
  • Medicine(all)

Fingerprint Dive into the research topics of 'FRETS-VWF73 rather than CBA assay reflects ADAMTS13 proteolytic activity in acquired thrombotic thrombocytopenic purpura patients'. Together they form a unique fingerprint.

  • Cite this